Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study by Nicola Bizzaro et al.
RESEARCH ARTICLE Open Access
Anti-cyclic citrullinated peptide antibody titer
predicts time to rheumatoid arthritis onset in
patients with undifferentiated arthritis: results
from a 2-year prospective study
Nicola Bizzaro1*†, Elena Bartoloni2†, Gabriella Morozzi3, Stefania Manganelli3, Valeria Riccieri4, Paola Sabatini5,
Matteo Filippini6, Marilina Tampoia7, Antonella Afeltra8, Giandomenico Sebastiani9, Claudia Alpini10, Vittorio Bini11,
Onelia Bistoni2, Alessia Alunno2 and Roberto Gerli2, for
the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA Group)
Abstract
Introduction: The diagnostic, predictive and prognostic role of anti-cyclic citrullinated peptide (CCP) antibodies in
rheumatoid arthritis (RA) patients is widely accepted. Moreover, detection of these antibodies in subjects
presenting with undifferentiated arthritis (UA) is associated with a significant risk to develop the disease. On the
other hand, clinical and prognostic significance of evaluating anti-CCP levels in subjects with inflammatory arthritis
at disease onset has not been fully clarified. The goal of this prospective study is to analyze the value and
prognostic significance of anti-CCP titer quantification in UA subjects.
Methods: Serial anti-CCP assays were measured in 192 consecutive patients presenting with UA lasting less than
12 weeks. Clinical and serological data and arthritis outcome were evaluated every 6 months until two years of
follow-up.
Results: Anti-CCP positivity, at both low and high titer, and arthritis of hand joints significantly predicted RA at two
years, risk increasing in subjects with high anti-CCP titers at baseline. Moreover, time to RA diagnosis was shorter in
patients with high anti-CCP2 titers at enrollment with respect to those with low antibody concentration.
Conclusions: Presence of anti-CCP antibodies, at both low and high concentration, is significantly associated with
RA development in subjects with recent onset UA. However, time interval from the onset of the first symptoms to
the fulfilment of the classification criteria appears to be directly related to the initial anti-CCP level.
Introduction
In recent years, the broad availability of specific serolo-
gical markers deeply changed the diagnostic approach to
rheumatoid arthritis (RA), a chronic inflammatory dis-
ease associated with a progressive and often disabling
course if not promptly recognized and effectively trea-
ted. In this setting, anti-citrullinated peptide antibodies
(ACPA), commonly detected by means of the second
generation anti-cyclic citrullinated peptide test (anti-
CCP2), represent a peculiar feature of RA patients [1].
To meet the need of improved diagnostic and prognos-
tic tests, the progressive evolution of the analytical
methods for ACPA detection, as measured by quantita-
tive immunometric assays, have led to a very high level
of diagnostic accuracy with a specificity of 95% to 97%
and a sensitivity of 67% to 80% [2,3]. The sensitivity
values are likely the highest obtainable in relation to the
close link existing between the production of ACPA and
genetic constitution [4]. At the moment, the anti-CCP2
antibody test yields higher specificity and comparable or
even higher sensitivity with respect to rheumatoid factor
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(RF) or other ACPA, including the recently discovered
anti-mutated citrullinated vimentin antibodies [5].
In established disease, it is has been widely demon-
strated that the presence, in particular at high levels, of
anti-CCP is associated with more severe clinical outcomes,
higher disease activity and worse radiographic progression
[6-9]. Moreover, retrospective studies have assessed their
predictive value demonstrating that anti-CCP can be
detected in the serum of subjects later developing RA up
to fourteen years before the first clinical symptoms, with
titer significantly increasing closer to disease onset [10,11].
Similar findings have been obtained in studies involving
patients with early disease, thus confirming the clinical uti-
lity of anti-CCP as a diagnostic and prognostic tool in sub-
jects presenting with RA lasting less than one or two years
[1,5]. As a consequence, the new 2010 RA Classification
Criteria, which have been updated in order to diagnose
RA in an earlier phase, included detection of ACPA as a
key item for diagnosing the disease [12].
Finally, anti-CCP antibodies may have an important role
in the diagnostic algorithm of subjects presenting with
undifferentiated arthritis (UA). Indeed, UA accounts for
30% to 50% of patients presenting to the rheumatologist
and has a variable natural course. In particular, progres-
sion to RA has been reported in only one-third of patients
after 1 year and in 40% after 3 years [13]. In order to mini-
mize the risk of diagnostic pitfalls and subsequent under-
or over-treatment, clinical, serologic and instrumental
markers have been employed to estimate the likelihood of
progression to RA in these subjects. Among these, serum
anti-CCP positivity at baseline has been demonstrated to
possess very high predictive and prognostic accuracy in
comparison to other markers [14]. Interestingly, a recent
study showed that early introduction of methotrexate
therapy in UA patients with circulating anti-CCP delays
evolution to RA, and prevents joint damage [15].
Although some questions remain unanswered regarding
the significance of anti-CCP detection in patients with
UA, quantification of anti-CCP serum level is now consid-
ered a key investigational issue and the important role
played by antibody level on disease outcome has been
underlined by the different scores attributed to antibody
serum levels in the new classification criteria for RA [12].
Indeed, in early RA lasting less than 1 year, it has been
demonstrated that anti-CCP positivity at any time is asso-
ciated with higher risk of radiographic damage at baseline
[16]. Interestingly, increase in antibody titer during the
first 3 years of follow up was shown to significantly corre-
late with radiographic progression after 5 years [16].
However, in a similar patient population, anti-CCP serum
levels did not seem to correlate with disease activity and
severity, thereby suggesting that anti-CCP-positive patients
with early RA have higher disease activity and severity
independent of antibody titer [17].
On the other hand, studies analyzing the value and
prognostic significance of anti-CCP titer quantification in
UA patients at disease onset are very few, and results
quite contradictory, mainly because of different study
design and population enrollment criteria. In UA patients
with evidence of circulating anti-CCP at disease onset, it
has been demonstrated that antibody status appears to
remain substantially stable during a disease course of up
to 5 years of follow up, with a rate of seroconversion ran-
ging from 1% to 9% [18-21]. Thus, the utility of anti-CCP
retesting during the disease course in patients presenting
with inflammatory arthritis is actually questionable and
not recommended. On the other hand, the clinical value
of anti-CCP levels at disease onset and influence of titer
changes over time on disease outcome have not been
fully clarified.
Therefore, the aim of this multicenter prospective study
was to analyze the value and prognostic significance of
anti-CCP titer quantification and monitoring in a cohort
of patients presenting with UA.
Material and methods
Study subjects
Consecutive patients with UA were recruited at nine
rheumatology units belonging to the Forum Interdiscipli-
nare per la Ricerca nelle Malattie Autoimmuni (FIRMA
group), an Italian association of hospital and university
experts in the field of autoimmune rheumatic diseases.
The cohort included patients aged more than 18 years
presenting with either mono-, oligo- or polyarticular
arthritis lasting less than 12 weeks, and not meeting the
1987 American College of Rheumatology (ACR) classifi-
cation criteria for RA, nor fulfilling any of the existing
classification criteria for other inflammatory rheumatic
disease. Evidence of radiographic joint damage or rheu-
matoid nodules represented exclusion criteria. Only non-
steroidal anti-inflammatory drugs (NSAIDs) or Cox-2
selective inhibitors (Coxibs) and/or low-dose of corticos-
teroids (CS) (prednisone < 15 mg a day or equivalent)
were allowed in the period from symptom onset to the
time of enrollment. Patient recruitment began in March
2007 and was stopped in May 2009 after the inclusion of
206 patients. Subjects were assessed by a trained rheuma-
tologist at baseline and every 6 months thereafter.
Follow-up was continued until the last enrolled patient
completed two years of follow-up. Demographic data
were assessed at baseline and clinical and serological data
were recorded at each visit. Diagnosis of RA or of any
other rheumatic or non-rheumatic disorder was per-
formed by the referring rheumatologists.
Each enrolled patient gave written consent prior to
being included in the study. Patient identity was not dis-
closed and the data were anonymously used in accordance
with the latest version of the Helsinki Declaration of
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human research ethics. Collection of patient samples was
carried out according to the University-Hospital of Udine
Ethic Committee regulations.
Methods
Serum samples were collected at baseline and every 6
months. Overall, therefore, four serum samples were
obtained from each patient. ACPAs were measured by
the routine commercial method used in each participat-
ing center, according to manufacturer’s instructions.
They were determined by CCP2-based assays, manufac-
tured by Phadia (Uppsala, Sweden) (three centers), Axis-
Shield (Dundee, UK) (three centers), Eurodiagnostica
(Nijmegen, The Netherlands) (two centers) and Inova
(San Diego, CA, USA) (one center). To harmonize and
compare results obtained by the different assays, anti-
CCP2 levels were expressed as a ratio, dividing the
observed absolute antibody amount by the cutoff value
of each commercial kit. Serum levels less than, or more
than three times the cutoff were considered low and
high, respectively.
IgM RF, erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) levels were locally determined by
each participating center. Since the nine centers
employed different analytical methods with different
cutoffs, RF, ESR and CRP values were also converted to
ratios, as described for anti-CCP2 values.
Statistical analysis
Student’s t-test and the Mann-Whitney test were used
to compare normally and non-normally distributed con-
tinuous variables respectively (deviation from the Gaus-
sian distribution were checked using the Shapiro-Wilk
test). The chi squared (X2) test with Yate’s continuity
correction was used to analyze categorical variables. To
estimate the survival function from the time of arthritis
onset to the time of RA diagnosis, the Kaplan-Meier
method was used. The risk of developing RA according
to CRP, RF, anti-CCP2, and arthritis of the hand joints,
was estimated by the Cox proportional hazard model,
first adding one variable at time (un-adjusted hazard
ratio, HR), and then all variables together (adjusted HR).
Biochemical variables were evaluated as categorical
variables and divided into three levels as suggested by
the ACR/European League Against Rheumatism
(EULAR) criteria. Two-tailed P-values lower than 0.05
were considered statistically significant. Calculations
were performed with Stata 8.2 software (Stata Corpora-
tion, College Station, Texas, USA).
Results
Among the 206 enrolled patients, 192 (93.2%) com-
pleted the study and 14 were lost during follow up,
mainly because they moved to another location. Table 1
shows the baseline characteristics of the patient cohort.
It includes 147 women and 45 men with a mean age of
52 ± SD, 16 years. Most patients had polyarthritis
(60.9%) and only 9.4% of them presented with monoar-
thritis at onset. In about two-thirds of the cases, joint
synovitis was localized at the hands.
A consistent number of patients (n = 79, 41.4%) were
positive for RF (mean ratio: 3.8 ± SD 8.2) and/or anti-
CCP2 (n = 80, 41.7%; mean ratio 7.8 ± SD 17) at base-
line. Among the RF-positive subjects, 67.1% displayed
high RF titers, while in the group of anti-CCP2-positive
subjects, an even higher percentage (83.8%) displayed
high anti-CCP2 levels in the serum. Many patients
(45.8%) were out of therapy, 66 patients (34.4%) were
taking NSAIDs or Coxibs, while a small number of sub-
jects were taking CS in combination with, or without
NSAIDs/Coxibs.
As depicted in Table 2, 72/192 (37.5%) patients had
progressed to RA at 2 years from recruitment: 26 at 6
months, 20 at 12 months and 26 at 24 months. Among
those who did not develop RA, a rheumatic disease
other than RA (largely psoriatic arthritis and undifferen-
tiated connective tissue disease) was diagnosed in 30
patients (15.6%). In addition, arthritis was transitory and
eventually remitted in 32 patients (16.7%), while no defi-
nite diagnosis was made at 24 months in 58 of them
(30.2%) and a diagnosis of UA was thus maintained.
Table 3 shows the baseline characteristics of the
patient cohort who developed RA at the end of the
study, compared to the patients who did not. Age, gen-
der and number of involved joints at presentation did
not help in distinguishing patients developing RA during
follow up, while hand articular involvement was more
frequent at baseline in subjects developing RA. More-
over, higher initial levels of CRP but not of ESR, were
associated with a higher possibility of developing RA. In
addition, the majority of patients with a diagnosis of RA
at the end of the study were RF-positive and had much
higher titers of RF at presentation than patients who did
not develop the disease. However, the percentage of
patients with either low or high RF titer at symptom
onset in RA and non-RA patients was similar.
Among subjects who developed RA, the majority had
anti-CCP2 at presentation (73.6%), while only 22.5% of
non-RA patients displayed these antibodies (P < 0.0001).
Interestingly, although the anti-CCP2 mean ratio at
baseline in the RA cohort was up to 3.5-fold higher
than that observed in the non-RA group (P < 0.0001),
the percentage of patients with either low or high anti-
CCP2 titers at enrollment did not differ in the RA and
non-RA groups. Furthermore, the presence at recruit-
ment of a single positivity for RF, without evidence for
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anti-CCP2, was not able to discriminate between
subjects who would or would not develop RA, while the
percentage of anti-CCP2-positive patients was higher
in the RA cohort independent of the evidence of
RF-positivity. It is of note that the percentage of anti-
CCP2-positive patients and anti-CCP2 titers remained
substantially stable during follow up (data not shown).
Finally, the initial treatment with NSAIDs/Coxibs and/
or CS did not appear to influence the subsequent devel-
opment of arthritis (data not shown).
On univariate regression analysis, inflammatory invol-
vement of the hand joints, high CRP levels, and RF and
anti-CCP2 at both low and high titers were predictive of
RA development (Table 4). However, on multivariate
analysis adjusted for the covariates CRP, RF, anti-CCP2
and arthritis of the hand joints, only arthritis of the
hand joints and anti-CCP2, at both low and high titers
predicted RA, with a risk of 3.2 for low, and 4.3 for high
anti-CCP2 titers at baseline.
As shown in Figure 1, time from presentation to diag-
nosis of RA was related to anti-CCP2 levels at baseline,
since this period was shorter in patients having high
anti-CCP2 titers at enrollment with respect to those dis-
playing basal low anti-CCP2 levels. However, the RA-
free survival curve in the two groups overlapped at the
end of 2-year follow up.
Table 2 Diagnosis at the end of follow up (2 years)
Diagnosis Number of patients (%)
Rheumatoid arthritis 72 (37)
Undifferentiated arthritis 58 (30)
Remission 32 (17)
Psoriatic arthritis 11 (6)
Undifferentiated connective tissue disease 8 (4)
Fibromyalgia 4 (2)
Spondiloarthritis 2 (1)
Viral arthritis (EBV) 1 (0.5)
Systemic lupus erythematosus 1 (0.5)
Osteoarthritis 1 (0.5)
Sarcoidosis 1 (0.5)
Primary Sjögren’s syndrome 1 (0.5)
Total 192 (100)
EBV, Epstein-Barr virus.
Table 1 Baseline demographic, clinical and serological characteristics of the 192 patients with undifferentiated
arthritis
Characteristics Baseline values Percent patients
Age, years, mean ± SD 52 ± 16 na
Female, n 147 76.6
Monoarthritis, n 18 9.4
Oligoarthritis, n 57 29.7
Polyarthritis, n 117 60.9
Arthritis of hand joints, n 126 65.6
CRP
Positive, n 98 51.0
Ratio, median (IR) 1.1 (0.6-4.1) na
ESR
Increased, n 103 53.6
Ratio, median (IR) 22.5 (14-40) na
Rheumatoid factor
Positive 79 (41.4)
Ratio, median (IR) 0.7 (0.5-3.9) na
Low titer on total positive 26 (32.9)
High titer on total positive 53 (67.1)
ACPA
Positive, n 80 (41.7)
Ratio, median (IR) 0.5 (0.3-7.8) na
Low levels on total positive, n 13 (16.2)
High levels on total positive, n 67 (83.8)
Baseline therapy
None, n 88 (45.8)
NSAIDs/Coxibs, n 66 (34.4)
Corticosteroids, n 10 (5.2)
n, number of patients; CRP, C-reactive protein; IR, interquartile range; ESR, erythrocyte sedimentation rate; ACPA, anti-citrullinated peptide antibodies; NSAID, non-
steroidal anti-inflammatory drug; Coxib, Cox-2 selective inhibitor; na, not applicable.
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During the study period, patients were treated with
anti-inflammatory drugs, or disease modifying anti-rheu-
matic drugs (DMARDs), but there was no relationship
between the change in anti-CCP2 levels and the therapy
introduced (data not shown). Moreover, no significant
relationship was detected between anti-CCP2 titer and
the other parameters, in particular ESR and CRP (data
not shown).
Discussion
In recent years, the generation of serological tests for accu-
rate ACPA detection lead to an impressive improvement in
the diagnosis of inflammatory articular disorders. In parti-
cular, anti-CCP2 assays are helpful in various clinical set-
tings, such as early diagnosis of RA, diagnosing RF-negative
RA and differentiating other RF-positive arthritis, such as
hepatitis C virus-related joint involvement [1,22]. Moreover,
in subjects presenting with UA, evidence of anti-CCP2
positivity at baseline appears to have relevant diagnostic,
predictive and prognostic value [16,23-25]. On the other
hand, major uncertainty remains about the clinical and
prognostic significance of anti-CCP2 titer in UA subjects,
in particular in subjects presenting with borderline antibody
values. These doubts are further strengthened by the obser-
vation that many non-RA sera with low ACPA levels bind
equally to citrullinated and non-citrullinated peptides and
that low ACPA levels may not discriminate between true
and false positive results [26]. Thus, specificity of low-posi-
tive samples remains a diagnostic issue.
In the present prospective study recruiting subjects with
recent onset UA, 37% of them developed RA at 2 years,
while 30% maintained persistent UA. The available data in
the literature show that the percentage of UA subjects
developing RA or persistent arthritis is highly variable,
ranging from 7% to 72%. The wide range of RA diagnoses
may be related to different lengths of follow up, which in
particular, was shorter in many studies with respect to
that of our investigation [27-30]. Indeed, it is conceivable
that some UA patients may experience progression to RA
after more than 1 year of follow up. In addition, the design
of some studies also did not rule out baseline recruitment
of subjects fulfilling the ACR 1987 RA classification cri-
teria. The introduction of DMARDs in this group of
patients at enrollment may hamper the interpretation and
comparison of the data [21,29,31]. Finally, the pattern of
inflammatory joint involvement, and most importantly,
Table 3 Baseline demographic, clinical and serological characteristics of the 192 patients subdivided according to
diagnosis after 24 months
Parameter at onset Patients developing RA Patients not developing RA P
Number % Number %
Patients 72 37.5 120 62.5
Age, years, mean ± SD 52 ± 16 na 52 ± 15 na 0.895
Female 57 79.2 90 75.0 0.628
Monoarthritis 7 9.7 11 9.2 0.999
Oligoarthritis 16 22.2 41 34.2 0.111
Polyarthritis 49 68.1 68 56.6 0.158
Hand joints arthritis 55 76.4 71 59.2 0.023
CRP+ 41 56.9 58 48.3 0.314
CRP ratio, median (IR) 1.9 (0.6-1.9) 0.9 (0.6-2.6) 0.031
ESR increase 38 52.8 65 54.2 0.970
ESR median (IR) 24 (12.3-53.3) 22.5 (16.0-38) 0.773
RF+ 45 62.5 34 28.3 < 0.0001
RF ratio, median (IR) 2.3 (0.6-7.8) 0.6 (0.5-1.2) < 0.0001
RF low+/total RF+ 11 24.4 15 44.1 0.109
RF high+/total RF+ 34 75.5 19 55.9
ACPA+ 53 73.6 27 22.5 < 0.0001
ACPA ratio, median (IR) 5 (0.6-14.3) 0.5 (0.3-0.8) < 0.0001
ACPA low+/total+ 7 13.2 6 22.2 0.476
ACPA high+/total+ 46 86.8 21 77.8
RF+/ACPA- 2 2.8 12 10 0.115
RF-/ACPA+ 10 13.9 5 4.2 0.031
RF+/ACPA+ 43 59.7 21 18.3 < 0.0001
RF-/ACPA- 17 23.6 81 67.5 < 0.0001
RA, rheumatoid arthritis; CRP, C-reactive protein; IR, interquartile range; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; ACPA, anti-citrullinated
peptide antibodies; NA, not applicable.
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the duration of joint symptoms at inclusion ranging from
more than four weeks to less than 3 years, produced quite
variable differences in results between different studies. In
this setting, the very short duration of UA, the exclusion
of patients with definite arthritis and the inclusion of all
patterns of arthritis, which characterize the enrolled popu-
lation, may represent a potential strength of this study.
The analysis of clinical and serological characteristics
of our UA patients at presentation showed that those
developing RA at 2 years more frequently had inflam-
matory involvement in the hand and higher CRP, RF
and anti-CCP2 titers in comparison to non-RA subjects.
Although the same items predicted RA on univariate
analysis, only patients with hand arthritis and anti-CPP2
Free Survival Time in Months (t)
























Low positive CCP ratio
High positive CCP ratio
Figure 1 Time to reach rheumatoid arthritis (RA) diagnosis according to anti-cyclic citrullinated peptide 2 (CCP2) levels in 192 patients
with undifferentiated arthritis. Data were analyzed by Kaplan-Meier analysis and the log-rank test.
Table 4 Risk of developing rheumatoid arthritis: Cox regression univariate and multivariate hazards ratio (HR) analysis
HR (95% CI)
Unadjusted





Low + 0.720 (0.362, 1.434) 0.350 0.875 (0.423, 1.811) 0.719
High+ 1.737 (1.049, 2.877) 0.032 1.827 (0.950, 3.514) 0.071
RF
Negative 1 1
Low+ 2.020 (1.001, 4.073) 0.050 0.791 (0.248, 2.522) 0.692
High+ 3.097 (1.867, 5.137) < 0.001 0.729 (0.219, 2.431) 0.607
ACPA
Negative 1 1
Low + 3.360 (1.412, 7.998) 0.006 3.187 (1.257, 8.077) 0.015
High + 4.613 (2.698, 7.887) < 0.001 4.324 (2.023, 9.245) < 0.001
Hand joints arthritis 1.871 (1.083, 3.232) 0.025 2.140 (1.128, 4.059) 0.020
CRP, C-reactive protein; RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibodies.
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positivity presented a significantly increased risk of
developing RA on multivariate analysis.
The percentage of anti-CCP2-positive UA patients
included in the present study was within the range of
anti-CCP2 positivity described in UA cohorts in other
studies (14% to 59%). In this setting, it is of note that
the proportion of anti-CCP2-positive patients at baseline
was higher in subjects with RA diagnosis with respect to
non-RA subjects, independent of RF positivity, while the
percentage of patients with single positivity for RF (anti-
CCP2-negative) was similar in the RA and non-RA
groups. Moreover, CRP and ESR levels do not appear to
have an effect on risk of progression to RA. Taken
together, these observations confirm the key prognostic
role of anti-CCP2 for RA diagnosis, rather than RF and
inflammatory parameters.
In agreement with previous studies [21,32], we did not
observe any effect of age and gender on anti-CCP2
levels in the different patient groups. On the other
hand, the genetic background may exert a relevant
adjunctive role in the risk of disease development. Inter-
estingly in fact, anti-CCP2-positive UA patients who will
develop RA display reactivity against a significant larger
number of citrullinated epitopes, namely vimentin, fibri-
nogen and a-enolase, with respect to anti-CCP2-positive
patients not evolving toward RA at one year of follow
up, thus postulating a very distinct immunological reac-
tivity profile at disease onset [33].
Recent prospective studies showed that higher baseline
anti-CCP titer is significantly correlated to increased
likelihood of persistent arthritis or RA development in
cohorts of subjects presenting with UA [21,27,29,30]
(Table 5). Moreover, the likelihood of persistent arthritis
increased with increasing ACPA levels, with a 14-fold
risk depicted in subjects with anti-CCP > 250 U/ml [29].
Few of these studies, however, performed a serial analy-
sis of anti-CCP2 titer during follow up, as was per-
formed in our population [21,31]. In the present cohort,
the percentage of patients with low or high anti-CCP2
titer was not different in the RA and non-RA groups
after 2 years of observation. This reflects the substantial
stability of anti-CCP2 levels over time, as has also been
demonstrated in other studies [18,19,21].
One of the most interesting findings of the present
study, however, is the demonstration that progression to
RA in UA patients is more rapid in those with higher
anti-CCP2 levels. To our knowledge, this is the first
demonstration that high anti-CCP2 levels at baseline
correlate with shorter time to RA diagnosis in subjects
with recent onset UA. This conclusion appears to be
supported by the data of a differently designed study in
a cohort of healthy women, showing that detection of
high anti-CCP2 levels in samples stored at baseline was
strongly associated with the time to RA diagnosis,
higher values being predictive of shorter time to disease
onset [34].
Anti-CCP concentration does not appear to correlate
with clinical disease outcomes or radiographic progres-
sion, in particular in studies analyzing serial antibody
measurements over time. Neither low nor moderate to
high anti-CCP titer, or relative change in antibody levels,
correlated with higher risk of radiographic damage, or
Table 5 Studies evaluating the significance of anti-CCP titer in patients with undifferentiated arthritis (UA)
Author
[ref]




UA outcome Anti-CCP titer significance
Kudo-
Tanaka [27]
146 ≥ 2 Sj ≤ 2 yr 1 yr ≥ 5 U/ml no
serial assay
17% 12% RA 37% non-RA
41% UA
164 ± 136 RA vs 55 ± 72
non-RA/UA P = 0.017
Guzian [18] 253 (83% RA
baseline)
≥ 3 Sj ≤ 1 yr 30 mo. ≥ 20 U/ml
serial assay
(0.30 mo.)
38% 17% RA No correlation low-high
CCP/DAS28, HAQ, erosions
Ursum [31] 545 ≥ 2 Sj ≤ 3 yr 2 yr ≥ 5 U/ml serial
assay (0.1 yr)




Emad [28] 69 ≥ 1 Sj ≤ 1 yr 1 yr ≥ 2.9 U/ml no
serial assay
59% 26% RA 6% PsA 41%
UA 26% remission
Correlation CCP titer/Sj, Tj,
ESR, erosions






≥ 5 U/ml no
serial assay
34% 7% RA 13% ≥ 4Sj 80%
no-arthritis
Median 141 arthritis vs 31





≥ 1 Sj ≤ 16 wk 1 yr ≥ 25 U/ml no
serial assay
16% 46% persistent 54% self-
limiting
25-100 OR 4.4 101-250 OR =
9.4 > 250 OR = 14 for
persistence
Burr [21] 640 (49% RA
baseline)
≥ 2 Sj ≥ 4 wk 5 yr ≥ 5 U/ml serial
assay (0.5 yr)




192 ≥ 1 Sj ≤ 12 wk 2 yr serial assay
(0.6,12,18,24
mo.)
42% 37% RA 30% UA 17%
self-limiting 16% non-
RA RD
Correlation titer/time to RA
onset and RA development
RA, rheumatoid arthritis; FU, follow up; Sj, swollen joint; CCP, cyclic citrullinated peptide; Tj, tender joint; DAS28, disease activity score; HAQ, health assessment
questionnaire; PsA: psoriatic arthritis; RD, rheumatic disease; SHS, Sharp Heijde Score; ESR, erythrocyte sedimentation rate; HR, hazard ratio; OR, odds ratio.
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with outcome measures of disease activity and severity
[18,31]. However, in a recent prospective study with a
follow up of 5 years, anti-CCP concentration more than
four times the upper normal limit was associated with a
ten-fold increased risk of erosive disease [21]. The
longer follow up characterizing this study may explain
these conflicting data.
Conclusions
The results of the present study further support the value
of testing anti-CCP antibodies in subjects presenting with
UA. In particular, they confirmed that recent onset UA
patients displaying anti-CCP antibodies have a significantly
increased risk of developing RA rather than non-RA
inflammatory/autoimmune diseases at 2 years. This is con-
firmed not only in patients with high, but also those with
low antibody titer. However, initial anti-CCP levels appear
to be of great importance in predicting the interval time to
disease onset, since a delay in RA diagnosis could occur in
subjects with low antibody levels at symptom onset. This
suggests the need of closer follow up of these UA patients.
Further studies, however, are needed to evaluate the influ-
ence of a peculiar genetic background on antibody level
and to explore therapeutic interventions that can be direc-
ted toward specific patient subgroups considered to have
the highest risks.
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